 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Carcinoid Tumors
Carcinoid Tumors occur most often in the stomach or intestines. They are also sometimes found in the lungs. These tumors make hormones or other substances that usually only occur in very small amounts in the body. In some people, the excess hormones are associated with other symptoms, such as flushes (turning red and feeling warm) and diarrhea
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Carcinoid Tumors Study CSOM230C2303
The purpose of this clinical trial is to compare the two drugs pasireotide LAR and octreotide LAR to find out which of these medicines gives the best relief from the diarrhea and flushing symptoms in participants with carcinoid disease who are not responding to other drugs. Pasireotide is a new medicine which has not yet been approved by Health Authorities and therefore it is not currently available for sale in any country. Octreotide has been approved by Health Authorities and is available for sale, however, the dose to be used in this study, 40 mg, has not been approved by Health Authorities for sale.
Trial phase: Phase 3 Participation Duration: Participants will be asked to visit the study site 10 times over about 10 months. Each visit should take about 2 hours. During the first month, participants will be required to make 3 visits, and then one visit per month thereafter. At the end of the study, participants will have an option to continue the study (in the extension portion) for another 24 months. Protocol Number: Carcinoid Tumors Study CSOM230C2303 |
